mJOULE is a dual wavelength platform designed to fit any plastic surgery practice and medical spa facility.
Medical and aesthetic laser manufacturer Sciton Inc has introduced a new dual wavelength platform named mJOULE. The dual wavelength platform is designed to fit any practice. It houses the latest non-ablative fractional wavelength, MOXI, and a new intense pulsed light (IPL), BBL HERO.
“1927 nm is a winner, BBL plus 1927 nm (MOXI) equals an awesome, delegatable treatment,” says Elizabeth L. Tanzi, MD, FAAD, director Capital Laser and Skin Care, in a release. “Between Sciton’s MOXI, HALO, and Erbium Fully Ablative Laser Platform, all the resurfacing options are covered by one company. It’s the full toolbox.”
MOXI was developed for active individuals looking to correct the initial signs of sun damage and aging by fixing uneven pigmentation and improving the general tone and texture of skin. Improvements can be noticed after a single treatment, according to Sciton.
“The mJOULE’s MOXI addresses a gap in treatment offerings by delivering a time effective solution for our customers, a progressive alternative for their patients and an exciting advancement in our field,” says Robb Brindley, Sciton vice president of North American sales, in a release.
MOXI is manufactured to deliver non-ablative laser energy to revitalize a patient’s skin, no matter the season, age, or skin type. It takes under 30 minutes.
BBL HERO treats the entire body with Forever Young BBL+ and Forever Body, designed to deliver dramatic tonal and textural improvements anywhere on the body.
“BBL HERO is the most significant advance in pulsed broad-spectrum light in 20 years,” says board certified dermatologist Patrick Bitter, MD, in a release, adding that he is excited to add the “game changing technology” to his Los Gatos practice. “When my patients look at their skin post treatment they just say, ‘AMAZING!’ They are seeing smoother, clearer, younger and healthier looking skin after just one treatment with BBL HERO.”
Sciton works hand in hand with our physician partners to drive visionary innovation that is founded on science and uncompromised in quality, Brindley adds. “The future of aesthetic medicine is brighter than ever, and we are well positioned to release multiple products during a critical time in our industry.”